Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Halima El-Omri"'
Autor:
Dina Sameh Soliman, Samah Kohla, Shehab Fareed, Susanna Akiki, Aliaa Amer, Ibrahim Ganwo, Prem Chandra, Halima El-Omri, Feryal Ibrahim
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 14, Iss 1 (2022)
Sideroblastic anemia (SA) is a rare heterogenous group of inherited and acquired bone marrow disorders. We retrospectively studied the clinicopathologic characteristics, cytogenetic findings, and disease outcome of patients with acquired sideroblasti
Externí odkaz:
https://doaj.org/article/9db95e8f403a434d8aeb838ea0e8ef01
Autor:
Dina Sameh Soliman, Ahmad Al-Sabbagh, Feryal Ibrahim, Amna Gameil, Mohamed Yassin, Halima El-Omri
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
Background. Mast cell leukaemia is a unique disease among hematopoietic neoplasms, being one of the rarest leukaemia subtypes. In addition, its prompt diagnosis is usually challenging. This is due to its heterogeneity in clinical presentations and cy
Externí odkaz:
https://doaj.org/article/7c2e44a17968499cb2aebfdffdb87b99
Autor:
Dina S. Soliman, Shehab Fareed, Einas Alkuwari, Halima El-Omri, Ahmad Al-Sabbagh, Amna Gameel, Mohamed Yassin
Publikováno v:
Clinical Medicine Insights: Blood Disorders, Vol 2016, Iss 9, Pp 23-28 (2016)
Externí odkaz:
https://doaj.org/article/729f618858004dbcbdaa0d9afcbe22a1
Autor:
Feryal A. Ibrahim, Vignesh Shanmugam, Aliaa Amer, Halima El-Omri, Ahmad Al-Sabbagh, Ruba Y. Taha, Dina S. Soliman
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2015, Iss 9, Pp 123-128 (2015)
Externí odkaz:
https://doaj.org/article/59d6b4ef60f647c6bda519f6aa12c157
Autor:
Feryal Abbas Ibrahim Hilmi, Ahmad Al-Sabbagh, Dina Sameh Soliman, Hesham Al Sabah, Omar Mohammad Ismail, Mohamed Yassin, Halima El-Omri
Publikováno v:
Clinical Medicine Insights: Blood Disorders, Vol 10 (2017)
Systemic mastocytosis (SM) is a condition associated with clonal neoplastic proliferation of mast cells. In up to 40% of systemic mastocytosis cases, an associated clonal hematological disease of non–mast cell lineage, such as acute myeloid leukemi
Externí odkaz:
https://doaj.org/article/1c4a8d0dc3aa4c90b6d339ef5915a125
Autor:
Sarah A. ElKourashy, Dina Soliman, Abdelfatteh El Omri, Ruba Y. Taha, Hesham Elsabah, Hind Alashi, Prem Chandra, Halima El Omri
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Background In MENA region, there is a lack of evidence on Primary Myelofibrosis (PMF), leading to its underrepresentation in medical literature. This study marks the first comprehensive report on PMF data in Qatar, presenting findings from a single-c
Externí odkaz:
https://doaj.org/article/5d8981be45304e00a10210e9f5b2a3fa
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionVenetoclax is a BCL-2 inhibitor with proven efficacy in patients with multiple myeloma (MM) and translocation t(11;14). However, its role in plasma cell leukemia (PCL) remains unclear. Herein, we aimed to report a case of relapsed MM with
Externí odkaz:
https://doaj.org/article/470c774a7af44ec1ad222975166f1030
Autor:
Murtadha K. Al-Khabori, Ahmad Alhuraiji, Arif R. Alam, Faraz A. Khan, Halima El Omri, Hani Y. Osman, Hasan M. AaL Yaseen, Mahdiya Pir Al Bulushi, Ramesh K. Pandita, Mahmoud M. Marashi
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEAML is a heterogeneous hematologic malignancy. Region-specific recommendations for AML management can enhance patient outcomes. This article aimed to develop recommendations for the Gulf Cooperation Council (GCC) countries.METHODSTen AML panel
Externí odkaz:
https://doaj.org/article/d42eb2fa89c7415aa1320ed40b7819d9
Autor:
Halima El Omri, Regina Padmanabhan, Ruba Y. Taha, Nancy Kassem, Hesham Elsabah, Anil Yousaf Ellahie, Antonio J.J. Santimano, Muna A. Al-Maslamani, Ali S. Omrani, Adel Elomri, Abdelfatteh El Omri
Publikováno v:
Journal of Infection and Public Health, Vol 17, Iss 1, Pp 152-162 (2024)
Background: The use of ill-suited antibiotics is a significant risk factor behind the increase in the mortality, morbidity, and economic burden for patients who are under treatment for hematological malignancy (HM) and bloodstream infections (BSI). S
Externí odkaz:
https://doaj.org/article/de080622001e4224b0cc8e309bdba180
Autor:
Hesham Elsabah, Halima El Omri, Elmukhtar Habas, Ruba Y. Taha, Sarah A. ElKourashy, Feryal Ibrahim, Abdulqadir J. Nashwan, Nancy Kassem, Laxmi Ojha, Rajvir Singh, Rola Ghasoub, Abdelfatteh El Omri
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundMultiple myeloma (MM) is one of the most common hematological malignancies globally, and it is projected to increase in the coming years. It occurs more frequently in males and affects older individuals. Presenting symptoms can range from b
Externí odkaz:
https://doaj.org/article/d3612795947545d28ef6dbfdd55556e2